You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FLT3

Showing 26 - 50 of 670
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
Has Results
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Feb 6, 2022

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Patterns and Key Healthcare Resource Use in Acute Myeloid

Completed
  • Acute Myeloid Leukemia (AML)
  • Treatment patterns among AML patients
  • AML-related healthcare resources
  • Charlotte, North Carolina
    Sermo
Jan 25, 2022

NSCLC (NSCLC) Trial in Bronx (FLT3 Ligand Therapy (CDX-301), Stereotactic Body Radiotherapy (SBRT))

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • FLT3 Ligand Therapy (CDX-301)
  • Stereotactic Body Radiotherapy (SBRT)
  • Bronx, New York
    Montefiore Medical Center
Nov 5, 2021

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
May 23, 2022

B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

Not yet recruiting
  • B7-H3-positive Relapsed/ Refractory Neuroblastoma
  • T cell injection targeting FLT3 chimeric antigen receptor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Nov 1, 2022

Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia Trial in Columbus (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jan 4, 2022

Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma Trial in New York (Pembrolizumab, Flt3L,

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 18, 2021

Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Chengdu, Sichuan, China
    West China hospital of Sichuan University
Nov 1, 2021

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)

Terminated
Has Results
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +7 more
Mar 14, 2022

Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly

Completed
Has Results
  • Cutaneous Melanoma
  • +11 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +2 more
  • Chicago, Illinois
  • +6 more
Nov 10, 2021

Pancreatic Adenocarcinoma Trial in Dallas (drug, procedure, other)

Completed
Has Results
  • Pancreatic Adenocarcinoma
  • 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
  • +3 more
  • Dallas, Texas
    UT Southwestern Medical Center
Oct 10, 2022

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation Trial in Worldwide (gilteritinib, LoDAC (Low Dose

Active, not recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Beijing, China
  • +47 more
Aug 17, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Italy (Cytarabine, Daunorubicin, Midostaurin)

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Bari, Italy
  • +19 more
Mar 1, 2022

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-500)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +9 more
Jun 27, 2023

Acute Leukemia, Relapse, Hematopoietic Stem Cell Transplantation Trial in Guangzhou (Sorafenib)

Recruiting
  • Acute Leukemia
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 30, 2021

Acute Myeloid Leukemia Trial in Ulm (chemo (Mitoxantrone, Cytarabine), Placebo, Crenolanib)

Terminated
  • Acute Myeloid Leukemia
  • chemotherapy (Mitoxantrone, Cytarabine)
  • +3 more
  • Ulm, Germany
    Ulm University Hospital
Sep 28, 2021

FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • FLT3 Gene Mutation Negative
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2022

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Graft Vs Host Disease Trial in Chapel Hill (Fluorothymidine (FLT))

Active, not recruiting
  • Graft Vs Host Disease
  • Fluorothymidine (FLT)
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Mar 21, 2022

Leukemia, Myeloid, Acute Trial in France (Ponatinib 30 MG)

Recruiting
  • Leukemia, Myeloid, Acute
  • Ponatinib 30 MG
  • Angers, France
  • +13 more
Aug 4, 2021

Advanced Solid Tumors Trial in United States (GS-3583)

Active, not recruiting
  • Advanced Solid Tumors
  • Grand Rapids, Michigan
  • +3 more
Jul 22, 2022

Acute Myeloid Leukemia Trial in Worldwide (Midostaurin, Placebo)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Hong Kong, Hong Kong
  • +40 more
Jan 20, 2023